{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:40:10Z","timestamp":1782261610551,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacokinetic-pharmacodynamic (PK\/PD) targets of vancomycin therapy have been recognized for methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections but not for other gram-positive bacterial infections. Therefore, we investigated whether vancomycin concentration targets such as the trough level and ratio of the area under the curve to minimum inhibitory concentration (AUC\/MIC) are associated with the treatment outcome in enterococcal bacteremia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort analysis enrolled patients with bacteremia caused by vancomycin-susceptible <jats:italic>Enterococcus faecium<\/jats:italic> and <jats:italic>Enterococcus faecalis<\/jats:italic> who were treated with vancomycin from January 2007 to December 2017 at a tertiary hospital located in Seoul, South Korea. Patients without vancomycin concentrations were excluded from the study. The primary outcome was 28-day all-cause mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 37 patients were enrolled\u201426 with <jats:italic>E<\/jats:italic>. <jats:italic>faecium<\/jats:italic> infection and 11 with <jats:italic>E<\/jats:italic>. <jats:italic>faecalis<\/jats:italic> infection. The 28-day all-cause mortality rate was 21.6\u2009%. In univariate analysis, vancomycin trough level (\u2264 15\u00a0\u00b5g\/mL; <jats:italic>p<\/jats:italic> = 0.042), age (<jats:italic>p<\/jats:italic> = 0.044), and septic shock (<jats:italic>p<\/jats:italic> = 0.049) were associated with 28-day mortality but not AUC24\/MIC (&gt; 389; <jats:italic>p<\/jats:italic> = 0.479). In multivariate analysis, vancomycin trough concentration (\u2264 15\u00a0\u00b5g\/mL; <jats:italic>p<\/jats:italic> = 0.041) and younger age (<jats:italic>p<\/jats:italic> = 0.031) were associated with 28-day mortality in patients with enterococcal bacteremia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, a vancomycin trough level of 15\u00a0\u00b5g\/mL or lower was associated with 28-day mortality in enterococcal bacteremia. However, relatively large prospective studies are needed to examine the efficacy of vancomycin PK\/PD parameters in patients with enterococcal bacteremia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06809-x","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T08:02:56Z","timestamp":1635235376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species"],"prefix":"10.1186","volume":"21","author":[{"given":"Yujin","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Hoon","family":"Rim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsuk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghoon","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaejee","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye","family":"Seong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Guk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Beack","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Su","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Sup","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Goo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"6809_CR1","unstructured":"Lebreton F, Willems RJL, Gilmore MS. Enterococcus Diversity, Origins in Nature, and Gut Colonization. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Boston; 2014."},{"issue":"9","key":"6809_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s10096-019-03605-z","volume":"38","author":"BH Ryu","year":"2019","unstructured":"Ryu BH, Hong J, Jung J, Kim MJ, Sung H, Kim MN, Chong YP, Kim SH, Lee SO, Kim YS, et al. Clinical characteristics and treatment outcomes of Enterococcus durans bacteremia: a 20-year experience in a tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2019;38(9):1743\u201351.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"6809_CR3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","volume":"37","author":"LM Weiner","year":"2016","unstructured":"Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014. Infect Control Hosp Epidemiol. 2016;37(11):1288\u2013301.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"6809_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/CMR.00058-18","volume":"32","author":"M Garcia-Solache","year":"2019","unstructured":"Garcia-Solache M, Rice LB. The Enterococcus: a Model of Adaptability to Its Environment. Clin Microbiol Rev. 2019;32:2.","journal-title":"Clin Microbiol Rev."},{"issue":"4","key":"6809_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","volume":"41","author":"L Clark","year":"2019","unstructured":"Clark L, Skrupky LP, Servais R, Brummitt CF, Dilworth TJ. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections. Ther Drug Monit. 2019;41(4):483\u20138.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"6809_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"6809_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/AAC.01485-12","volume":"57","author":"NE Holmes","year":"2013","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O\u2019Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, et al. Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"6809_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/0897190016642692","volume":"30","author":"CM Hale","year":"2017","unstructured":"Hale CM, Seabury RW, Steele JM, Darko W, Miller CD. Are Vancomycin Trough Concentrations of 15 to 20\u00a0mg\/L Associated With Increased Attainment of an AUC\/MIC >\/= 400 in Patients With Presumed MRSA Infection? J Pharm Pract. 2017;30(3):329\u201335.","journal-title":"J Pharm Pract"},{"issue":"3","key":"6809_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5114\/ait.2019.87362","volume":"51","author":"M Makmor-Bakry","year":"2019","unstructured":"Makmor-Bakry M, Ahmat A, Shamsuddin A, Lau CL, Ramli R. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients. Anaesthesiol Intensive Ther. 2019;51(3):218\u201323.","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"11","key":"6809_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"key":"6809_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"MN Neely","year":"2018","unstructured":"Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, Schumitzky A, Yamada W, Jones B, Minejima E. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62:2.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"6809_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6809_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332.","journal-title":"Am J Infect Control"},{"key":"6809_CR14","unstructured":"Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. Clinical and laboratory standards institute; 2019. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiSw6zK3urqAhVX62EKHTOIATMQFjABegQIARAB&url=https%3A%2F%2Fclsi.org%2Fmedia%2F2663%2Fm100ed29_sample.pdf&usg=AOvVaw0bK-ZFDfbqRfzJz03o_pWy. Accessed 26 July 2020."},{"issue":"1","key":"6809_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-0034-1397040","volume":"36","author":"NE Holmes","year":"2015","unstructured":"Holmes NE, Tong SY, Davis JS, van Hal SJ. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med. 2015;36(1):17\u201330.","journal-title":"Semin Respir Crit Care Med"},{"issue":"Suppl 1","key":"6809_CR16","first-page":"S35-9","volume":"42","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1:S35-9.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6809_CR17","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1128\/AAC.03147-14","volume":"60","author":"R Alvarez","year":"2016","unstructured":"Alvarez R, Lopez Cortes LE, Molina J, Cisneros JM, Pachon J. Optimizing the Clinical Use of Vancomycin. Antimicrob Agents Chemother. 2016;60(5):2601\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6809_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","volume":"52","author":"BT Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;52(6):805\u201310.","journal-title":"Int J Antimicrob Agents"},{"key":"6809_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/AAC.01602-17","volume":"62","author":"MTB Jumah","year":"2018","unstructured":"Jumah MTB, Vasoo S, Menon SR, De PP, Neely M, Teng CB. Pharmacokinetic\/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia. Antimicrob Agents Chemother. 2018;62:3.","journal-title":"Antimicrob Agents Chemother."},{"key":"6809_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40780-019-0138-2","volume":"5","author":"I Nakakura","year":"2019","unstructured":"Nakakura I, Sakakura K, Imanishi K, Sako R, Yamazaki K. Association between vancomycin pharmacokinetic\/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study. J Pharm Health Care Sci. 2019;5:8.","journal-title":"J Pharm Health Care Sci"},{"issue":"3","key":"6809_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","volume":"41","author":"S Zelenitsky","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock CDRG. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41(3):255\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"6809_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/j.1875-9114.2011.01017.x","volume":"32","author":"R Kullar","year":"2012","unstructured":"Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012;32(3):195\u2013201.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"6809_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/1973947814Y.0000000182","volume":"27","author":"L Meng","year":"2015","unstructured":"Meng L, Fang Y, Chen Y, Zhu H, Long R. High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis. J Chemother. 2015;27(4):213\u201320.","journal-title":"J Chemother"},{"issue":"6","key":"6809_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ijantimicag.2019.03.023","volume":"53","author":"N Petersiel","year":"2019","unstructured":"Petersiel N, Bitterman R, Manaa A, Nashashibi L, Moskovich O, Geffen Y, Polak D, Braun E, Neuberger A, Paul M. beta-lactam antibiotics vs. vancomycin for the early treatment of enterococcal bacteraemia: A retrospective cohort study. Int J Antimicrob Agents. 2019;53(6):761\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"6809_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000452427","volume":"44","author":"K Hammoud","year":"2016","unstructured":"Hammoud K, Brimacombe M, Yu A, Goodloe N, Haidar W, El Atrouni W. Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study. Am J Nephrol. 2016;44(6):456\u201361.","journal-title":"Am J Nephrol"},{"issue":"3","key":"6809_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2042018816638223","volume":"7","author":"O Bamgbola","year":"2016","unstructured":"Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136\u201347.","journal-title":"Ther Adv Endocrinol Metab."},{"issue":"7","key":"6809_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601\u201310.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"6809_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bjae.2018.09.006","volume":"19","author":"M Charlton","year":"2019","unstructured":"Charlton M, Thompson JP. Pharmacokinetics in sepsis. BJA Educ. 2019;19(1):7\u201313.","journal-title":"BJA Educ"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06809-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06809-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06809-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T08:03:03Z","timestamp":1635235383000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06809-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6809"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06809-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"20 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations under Ethics approval. The study was approved by the Institutional Review Board (IRB) of the Yonsei University Health System Clinical Trial Center (4-2020-0161). The study was retrospective and the study subjects were anonymized, the IRB waived the requirement for written informed consent from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Individual cannot be identified and therefore consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential competing interests with respect to the research, authorship, and publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1099"}}